A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition

PLoS Computational Biology

Volumn 7, Issue 2, 2011, Pages

  Bagheri, Neda ^a   Shiina, Marisa ^b   Lauffenburger, Douglas A ^a   Korn, W Michael ^b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; CELL PROLIFERATION; DIFFERENTIAL EQUATIONS; DISEASES; DYNAMICAL SYSTEMS; NONLINEAR EQUATIONS; ONCOLOGY; RADIOTHERAPY; VIRUSES;

CANCER THERAPY; CELL INTERACTION; CELL-CYCLE ARREST; CLINICAL TRIAL; COMPETING EFFECTS; COMPLEX NONLINEAR DYNAMICS; DYNAMICAL SYSTEMS MODEL; PHARMACOLOGICAL INHIBITION; RECEPTOR EXPRESSION; THERAPEUTIC EFFICACY;

TUMORS;

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; ONCOLYTIC ADENOVIRUS; ONYX 015; ANTINEOPLASTIC AGENT; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; COXSACKIE-ADENOVIRUS RECEPTOR; VIRUS RECEPTOR;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MATHEMATICAL MODEL; NONHUMAN; NONLINEAR SYSTEM; ONCOLYTIC VIROTHERAPY; PREDICTION; TUMOR CELL; TUMOR CELL DESTRUCTION; ADENOVIRUS; BIOLOGICAL MODEL; CELL CYCLE; CELL STRAIN HCT116; CELL SURVIVAL; COMPUTER SIMULATION; DRUG ANTAGONISM; DRUG EFFECT; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASM; PHYSIOLOGY; REPRODUCIBILITY; SIGNAL TRANSDUCTION; VIROLOGY; VIRUS REPLICATION;

ADENOVIRIDAE; COXSACKIEVIRUS;

ADENOVIRIDAE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL SURVIVAL; COMBINED MODALITY THERAPY; COMPUTER SIMULATION; HCT116 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MODELS, BIOLOGICAL; NEOPLASMS; NONLINEAR DYNAMICS; ONCOLYTIC VIROTHERAPY; RECEPTORS, VIRUS; REPRODUCIBILITY OF RESULTS; VIRUS REPLICATION;

EID: 79952461747     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1001085     Document Type: Article

References (36)

1. Guo ZS, Thorne SH, Bartlett DL, (2008) Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta 1785: 217-231.
2. Shirakawa T, (2008) The current status of adenovirus-based cancer gene therapy. Mol Cells 25: 462-466.
3. Cody JJ, Douglas JT, (2009) Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther 16: 473-488.
4. Toth K, Dhar D, Wold WS, (2010) Oncolytic (replication-competent) adenoviruses as anticancer agents. Expert Opin Biol Ther 10: 353-368.
5. Barker DD, Berk AJ, (1987) Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156: 107-121.
6. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, et al. (2004) Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6: 611-623.
7. Ries SJ, Brandts CH, Chung AS, Biederer CH, Hann BC, et al. (2000) Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med 6: 1128-1133.
8. Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, et al. (2004) A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 10: 958-966.
9. Galanis E, Okuno SH, Nascimento AG, Lewis BD, Lee RA, et al. (2005) Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther 12: 437-445.
10. Habib N, Salama H, Abd El Latif Abu Median A, Isac Anis I, Abd Al Aziz RA, et al. (2002) Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther 9: 254-259.
11. Makower D, Rozenblit A, Kaufman H, Edelman M, Lane ME, et al. (2003) Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res 9: 693-702.
12. Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, et al. (2000) A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 6: 798-806.
13. Reid T, Galanis E, Abbruzzese J, Sze D, Andrews J, et al. (2001) Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther 8: 1618-1626.
14. Vasey PA, Shulman LN, Campos S, Davis J, Gore M, et al. (2002) Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 20: 1562-1569.
15. Lacher MD, Tiirikainen MI, Saunier EF, Christian C, Anders M, et al. (2006) Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and Adenovirus Receptor in conjunction with reversal of epithelial-mesenchymal transition. Cancer Res 66: 1648-1657.
16. Anders M, Christian C, McMahon M, McCormick F, Korn WM, (2003) Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res 63: 2088-2095.
17. Cherubini G, Petouchoff T, Grossi M, Piersanti S, Cundari E, et al. (2006) E1B55K-deleted adenovirus (ONYX-015) overrides G1/S and G2/M checkpoints and causes mitotic catastrophe and endoreduplication in p53-proficient normal cells. Cell Cycle 5: 2244-2252.
18. Goodrum FD, Ornelles DA, (1999) Roles for the E4 orf6, orf3, and E1B 55-kilodalton proteins in cell cycle-independent adenovirus replication. J Virol 73: 7474-7488.
19. Machida CA, (2003) Viral vectors for gene therapy: methods and protocols Totowa, N.J. Humana Press pp. xv, 589.
20. Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, et al. (2001) A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 7: 120-126.
21. Biesecker M, Kimn JH, Lu H, Dingli D, Bajzer Z, (2010) Optimization of virotherapy for cancer. Bull Math Biol 72: 469-489.
22. Komarova NL, Wodarz D, (2010) ODE models for oncolytic virus dynamics. J Theor Biol 263: 530-543.
23. Mok W, Stylianopoulos T, Boucher Y, Jain RK, (2009) Mathematical modeling of herpes simplex virus distribution in solid tumors: implications for cancer gene therapy. Clin Cancer Res 15: 2352-2360.
24. Paiva LR, Binny C, Ferreira SC Jr, Martins ML, (2009) A multiscale mathematical model for oncolytic virotherapy. Cancer Res 69: 1205-1211.
25. Wein LM, Wu JT, Kirn DH, (2003) Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res 63: 1317-1324.
26. Tao Y, Guo Q, (2008) A mathematical model of combined therapies against cancer using viruses and inhibitors. Science in China Series A: Mathematics 51: 2315-2329.
27. Zurakowski R, Wodarz D, (2007) Model-driven approaches for in vitro combination therapy using ONYX-015 replicating oncolytic adenovirus. J Theor Biol 245: 1-8.
28. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, et al. (1999) Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5: 810-816.
29. Shepard RN, Ornelles DA, (2003) E4orf3 is necessary for enhanced S-phase replication of cell cycle-restricted subgroup C adenoviruses. J Virol 77: 8593-8595.
30. Zheng X, Rao XM, Gomez-Gutierrez JG, Hao H, McMasters KM, et al. (2008) Adenovirus E1B55K region is required to enhance cyclin E expression for efficient viral DNA replication. J Virol 82: 3415-3427.
31. Tseng JC, Granot T, DiGiacomo V, Levin B, Meruelo D, (2010) Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor. Cancer Gene Ther 17: 244-255.
32. Gurlevik E, Woller N, Struver N, Schache P, Kloos A, et al. (2010) Selectivity of Oncolytic Viral Replication Prevents Antiviral Immune Response and Toxicity, but Does Not Improve Antitumoral Immunity. Mol Ther pp. 1-11.
33. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, et al. (2000) A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19: 2-12.
34. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, et al. (1997) Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320-1323.
35. Lee JA, Spidlen J, Boyce K, Cai J, Crosbie N, et al. (2008) MIFlowCyt: the minimum information about a Flow Cytometry Experiment. Cytometry A 73: 926-930.
36. Shiina M, Lacher MD, Christian C, Korn WM, (2009) RNA interference-mediated knockdown of p21(WAF1) enhances anti-tumor cell activity of oncolytic adenoviruses. Cancer Gene Ther 16: 810-819.